MAP2K4 and breast carcinoma: Our results confirm for the first time that CBR3 promotes ADR resistance in breast cancer cells via regulation of the CBR3-AS1/miR-25-3p/MEK4/JNK1 axis, indicating that CBR3-AS1 has potential as a targetable oncogene and biomarker for breast cancer treatment.